CCL2 and cancer: MCP-1 supports evidence of chronic immune activation (Singh et al., 2021), and has been associated with fatigue and cognitive symptoms in adult cancer populations, making it a candidate biomarker for treatment-related immune dysregulation (Janelsins et al., 2022; Lyon et al., 2016).